Rezolute Q4 net loss widens to $24.4 mln

Rezolute

17/09/2025 21:15

Repeats to chain to alerts; no changes to text

Overview

Rezolute fiscal Q4 net loss widens to $24.4 mln from $23.0 mln a yr earlier

Operating expenses rise due to increased R&D and G&A costs

Cash and investments increase to $167.9 mln as of June 30, 2025

Outlook

Rezolute expects topline sunRIZE trial results in December 2025

Company anticipates upLIFT study results in H2 2026

Result Drivers

R&D EXPENSES - Increased due to higher clinical trial activities, manufacturing costs for ersodetug, and employee-related expenses

G&A EXPENSES - Rise attributed to professional fees and increased headcount

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.26
Q4 Net Income
-$24.39 mln
Q4 Income From Operations
-$25.85 mln
Q4 Operating Expenses
$25.85 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Rezolute Inc is $13.00, about 40.6% above its September 16 closing price of $7.72

Press Release: ID:nGNX7NncV

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)